Ensysce Biosciences accelerates PF614-MPAR-102 study with full Part 2 enrollment

Ensysce Biosciences (ENSC) has fully enrolled Part 2 of the critical three-part PF614-MPAR-102 clinical study to study the effect of food on the MPAR technology. PF614-MPAR has earned the FDA’s Breakthrough Therapy designation and is uniquely engineered using Ensysce’s proprietary TAAP and MPAR technologies. These platforms enable PF614-MPAR to maintain therapeutic efficacy while delivering built-in overdose protection when doses exceed prescribed amounts, whether accidentally or intentionally. A three-year grant from the National Institute on Drug Abuse, with second year funding recently announced1, continues to support this program through May 2027. This support will accelerate the clinical development of PF614-MPAR and could help launch a new era in pain relief with overdose protection.